WO2004004757A8 - Treatment for eye disorder - Google Patents

Treatment for eye disorder

Info

Publication number
WO2004004757A8
WO2004004757A8 PCT/US2003/020672 US0320672W WO2004004757A8 WO 2004004757 A8 WO2004004757 A8 WO 2004004757A8 US 0320672 W US0320672 W US 0320672W WO 2004004757 A8 WO2004004757 A8 WO 2004004757A8
Authority
WO
WIPO (PCT)
Prior art keywords
membrane
treatment
individual
energy source
eye disorder
Prior art date
Application number
PCT/US2003/020672
Other languages
French (fr)
Other versions
WO2004004757A1 (en
Inventor
Daniel M Schwartz
Scott Fraser
Robert H Grubbs
Justin P Gallivan
C J Yu
Original Assignee
Univ California
California Inst Of Techn
Daniel M Schwartz
Scott Fraser
Robert H Grubbs
Justin P Gallivan
C J Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, California Inst Of Techn, Daniel M Schwartz, Scott Fraser, Robert H Grubbs, Justin P Gallivan, C J Yu filed Critical Univ California
Priority to CA002491128A priority Critical patent/CA2491128A1/en
Priority to JP2004519718A priority patent/JP2005532393A/en
Priority to AU2003253767A priority patent/AU2003253767A1/en
Priority to EP03763073A priority patent/EP1539222A1/en
Publication of WO2004004757A1 publication Critical patent/WO2004004757A1/en
Publication of WO2004004757A8 publication Critical patent/WO2004004757A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Abstract

The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.
PCT/US2003/020672 2002-07-02 2003-07-01 Treatment for eye disorder WO2004004757A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002491128A CA2491128A1 (en) 2002-07-02 2003-07-01 Treatment for eye disorder
JP2004519718A JP2005532393A (en) 2002-07-02 2003-07-01 Treatment for eye disorders
AU2003253767A AU2003253767A1 (en) 2002-07-02 2003-07-01 Treatment for eye disorder
EP03763073A EP1539222A1 (en) 2002-07-02 2003-07-01 Treatment for eye disorder

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39350502P 2002-07-02 2002-07-02
US60/393,505 2002-07-02

Publications (2)

Publication Number Publication Date
WO2004004757A1 WO2004004757A1 (en) 2004-01-15
WO2004004757A8 true WO2004004757A8 (en) 2004-10-07

Family

ID=30115595

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/020672 WO2004004757A1 (en) 2002-07-02 2003-07-01 Treatment for eye disorder

Country Status (6)

Country Link
US (2) US7381404B2 (en)
EP (1) EP1539222A1 (en)
JP (1) JP2005532393A (en)
CN (1) CN1678342A (en)
CA (1) CA2491128A1 (en)
WO (1) WO2004004757A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004757A1 (en) * 2002-07-02 2004-01-15 The Regents Of The University Of California Treatment for eye disorder
KR20070011557A (en) 2004-05-07 2007-01-24 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Treatment of myopia
US7654540B2 (en) * 2004-06-18 2010-02-02 Bose Corporation Electromechanical transducing
US20070213693A1 (en) * 2004-08-27 2007-09-13 Ellex Medical Pty Ltd Selective ophthalmic laser treatment
JP2006195240A (en) * 2005-01-14 2006-07-27 Fuji Photo Film Co Ltd Tomographic imaging device
US7668342B2 (en) 2005-09-09 2010-02-23 Carl Zeiss Meditec, Inc. Method of bioimage data processing for revealing more meaningful anatomic features of diseased tissues
US7768652B2 (en) * 2006-03-16 2010-08-03 Carl Zeiss Meditec, Inc. Methods for mapping tissue with optical coherence tomography data
US20090209899A1 (en) * 2006-06-15 2009-08-20 Harry Unger Delivery system and process
DE102006030382A1 (en) * 2006-06-29 2008-01-03 Carl Zeiss Meditec Ag Method and device for optical detection on the eye
AT504159A1 (en) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc USE OF PROTEASES
US8043235B2 (en) * 2006-08-22 2011-10-25 Schwartz Donald N Ultrasonic treatment of glaucoma
EP2083777A4 (en) 2006-10-25 2011-01-05 Ellex R & D Pty Ltd Retinal regeneration
EP2120677B1 (en) * 2007-02-15 2018-03-21 The UAB Research Foundation Improved photobleaching method
AU2008255642B2 (en) * 2007-05-30 2013-03-07 Alpharet Pty Ltd Retinal rejuvenation laser
WO2010004365A1 (en) 2008-07-10 2010-01-14 Ecole Polytechnique Federale De Lausanne (Epfl) Functional optical coherent imaging
KR101018785B1 (en) * 2008-11-28 2011-03-03 삼성전기주식회사 Electromagnetic bandgap structure and circuit board
US8609729B2 (en) * 2009-04-15 2013-12-17 Sucampo Ag Method for treating macular degeneration
US9226654B2 (en) 2011-04-29 2016-01-05 Carl Zeiss Meditec, Inc. Systems and methods for automated classification of abnormalities in optical coherence tomography images of the eye
JP5977440B2 (en) 2012-04-27 2016-08-24 アイマゴ ソシエテ アノニムＡｉｍａｇｏ Ｓ．Ａ． Optical coherent imaging medical device
WO2014009859A2 (en) * 2012-07-10 2014-01-16 Aïmago S.A. Perfusion assessment multi-modality optical medical device
CN103705551A (en) * 2013-12-02 2014-04-09 黄丽娜 Novel GSTT (Gross Saponins of Tribulus Terrestris L) intravitreal injection drug delivery system and application thereof
CN103656621A (en) * 2013-12-02 2014-03-26 黄丽娜 Novel mouse nerve growth factor intravitreal injection drug delivery system and application thereof
CN103877430B (en) * 2014-04-20 2016-04-20 赵华 A kind of medicine and preparation method for the treatment of degeneration of macula
CN107735015B (en) 2015-05-07 2021-09-10 史赛克欧洲运营有限公司 Method and system for laser speckle imaging of tissue using a color image sensor
US11273072B2 (en) 2017-01-13 2022-03-15 Gyroscope Therapeutics Limited Suprachoroidal injection device
AU2018218588B2 (en) * 2017-02-09 2021-05-27 Altregen Co., Ltd. Composition comprising composite extract from ginseng/red ginseng and sea cucumber as effective ingredient for preventing or treating bruch's membrane hypofunction-related disease
EP3637069A4 (en) 2017-06-08 2021-09-08 Ushio Denki Kabushiki Kaisha Spectrum measurement method, spectrum measurement device, and broadband pulse light source unit
US20180360655A1 (en) * 2017-06-16 2018-12-20 Michael S. Berlin Methods and systems for oct guided glaucoma surgery

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6A (en) * 1836-08-10 Thomas blanghard
US220245A (en) * 1879-10-07 Improvement in provision-safes
US87985A (en) * 1869-03-16 Improved rotary metal-cotter
US138329A (en) * 1873-04-29 Improvement in wheel-plows
US91229A (en) * 1869-06-15 Improvement in feeding-device for machines for combing- cotton
US4944944A (en) * 1987-11-19 1990-07-31 Oklahoma Medical Research Foundation Dietary compositions and methods using bile salt-activated lipase
US20030087985A1 (en) 1990-10-15 2003-05-08 Hubbell Jeffrey A. Gels for encapsulation of biological materials
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5626863A (en) * 1992-02-28 1997-05-06 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5468505A (en) 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
DK0627911T3 (en) * 1992-02-28 2000-11-20 Univ Texas Photopolymerizable biodegradable hydrogels as tissue contact materials and controlled release carriers
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US20040138329A1 (en) 1992-04-20 2004-07-15 Board Of Regents Of The University Of Texas System Gels for encapsulation of biological materials
US5310764A (en) * 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
US5800373A (en) * 1995-03-23 1998-09-01 Focal, Inc. Initiator priming for improved adherence of gels to substrates
US5458505A (en) * 1994-02-03 1995-10-17 Prager; Jay H. Lamp cooling system
US5798349A (en) * 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5935942A (en) * 1994-12-14 1999-08-10 Zeimer; Ran Selective and non-invasive visualization or treatment of vasculature
JP4209941B2 (en) * 1995-03-23 2009-01-14 ジェンザイム・コーポレーション Undercoat redox and photoinitiator systems for improved adhesion of gels to substrates
US6461640B1 (en) * 1995-12-08 2002-10-08 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
US5756541A (en) * 1996-03-11 1998-05-26 Qlt Phototherapeutics Inc Vision through photodynamic therapy of the eye
US6059828A (en) * 1996-03-18 2000-05-09 Peyman; Gholam A. Macular indentor for use in the treatment of subretinal neovascular membranes
BR9811793A (en) * 1997-07-18 2000-09-26 Infimed Inc Biodegradable macromers for the controlled release of biologically active substances.
US6128525A (en) * 1997-07-29 2000-10-03 Zeng; Haishan Apparatus and method to monitor photodynamic therapy (PDT)
JP2001520979A (en) * 1997-10-27 2001-11-06 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Methods and pharmaceutical compositions for retinal wound closure
US6472541B2 (en) 1998-11-20 2002-10-29 The Regents Of The University Of California Protecting groups with increased photosensitivities
US6858229B1 (en) * 1999-04-26 2005-02-22 California Institute Of Technology In situ forming hydrogels
DE19920158A1 (en) * 1999-04-29 2000-11-02 Univ Schiller Jena Method and arrangement for determining fluorophores on objects, in particular on the living fundus
US6271233B1 (en) * 1999-08-10 2001-08-07 Ciba Vision Corporation Method for treating ocular neovascular diseases
US6267954B1 (en) * 1999-11-24 2001-07-31 Universite De Paris V Rene-Descartes Intraocular transplantation of encapsulated cells
CA2395567A1 (en) 2000-01-12 2001-07-19 Light Sciences Corporation Novel treatment for eye disease
US7011952B2 (en) * 2000-02-22 2006-03-14 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
US7291673B2 (en) 2000-06-02 2007-11-06 Eidgenossiche Technische Hochschule Zurich Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
JP2005511713A (en) 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア Treatment for age-related macular degeneration
WO2004004757A1 (en) * 2002-07-02 2004-01-15 The Regents Of The University Of California Treatment for eye disorder
US20040199130A1 (en) * 2003-04-03 2004-10-07 Chornenky Victor I. Apparatus and method for treatment of macular degeneration

Also Published As

Publication number Publication date
US8298521B2 (en) 2012-10-30
WO2004004757A1 (en) 2004-01-15
CN1678342A (en) 2005-10-05
CA2491128A1 (en) 2004-01-15
JP2005532393A (en) 2005-10-27
US7381404B2 (en) 2008-06-03
US20050048044A1 (en) 2005-03-03
US20080286255A1 (en) 2008-11-20
EP1539222A1 (en) 2005-06-15

Similar Documents

Publication Publication Date Title
WO2004004757A8 (en) Treatment for eye disorder
EA200400518A1 (en) METHODS OF TREATING EYE NONASCULAR DISEASES
BR9307077A (en) Process for adjusting the corneal shape of an eye and intrastromal corneal ring
BR0110505A (en) Ophthalmic Lens Systems
WO2006002366A3 (en) Biodegradable ocular devices, methods and systems
WO2003092584A3 (en) Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies
WO2006071548A3 (en) Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases
BRPI0406879A (en) Sustained release device and method for ocular release of adrenergic agents
ECSP055739A (en) NEUTRALIZATION ANTIBODIES AGAINST GDF-8, AND ITS USES
WO2004041067A3 (en) Prevention and treatment of synucleinopathic disease
BRPI0406880A (en) Sustained release device and method for ocular release of carbonic anhydrase inhibitors
EA200300560A1 (en) IMPROVED TREATMENT METHOD
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
DE602005020178D1 (en) 5,6,7-TRIHYDROXYPHEPTANIC ACIDS AND ANALOGS FOR THE TREATMENT OF EYE DISEASES AND DISEASES ASSOCIATED WITH HYPERPROLIFERATIVES AND ANGIOGENIC REACTIONS
MXJL06000001A (en) Method of preparing an aqueous meloxicam solution and aqueous solution thus produced.
AU2001267864A1 (en) Remedial agent for optic nerve disease and the like
DE69028877D1 (en) Use of phenylethanolamines for the manufacture of medicines for eye diseases
BR0214957A (en) Superoxide dismutase mimetics for the treatment of eye disorders and diseases
WO2003092701A3 (en) Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders
WO2022092907A3 (en) Plasma treatment device applicable to multiple parts of human body
BRPI0411427A (en) Nonsteroidal Anti-Inflammatory Agents Formulations for the Treatment of Pathological Eye Angiogenesis
DE60215864D1 (en) TREATMENT OF OCULAR NEOVASCULAR DISEASES
DE69930419D1 (en) USE OF HUMAN PROTEIN C FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF HEPARINE-INDUCED THROMBOCYTOPENIA
BRPI0417549A (en) superoxide dismutase mimetics for the treatment of optic and retinal nerve injury
BR0215752A (en) Pyanoindazoles and their use in the treatment of glaucoma

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 03/2004 UNDER (22) REPLACE "07 JULY 2003 (07.07.03)" BY "01 JULY 2003 (01.07.03)"

WWE Wipo information: entry into national phase

Ref document number: 2003253767

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004519718

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2491128

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020047021664

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003763073

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20038208113

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020047021664

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003763073

Country of ref document: EP